Jordi Bruix
www.bclc.cat
0000-0002-9826-0753
197 papers found
Refreshing results…
The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments
Exposure–response relationship of regorafenib efficacy in patients with hepatocellular carcinoma
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma
Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication
Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros
Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them
Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?
Reply:
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma
The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Reply to “Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing”
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium
Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients
Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, SEOM, SERAM, SERVEI y SETH
Inheriting a Jewel: A Thrilling Challenge
Missing publications? Search for publications with a matching author name.